Review of molecular diagnostics in multiple myeloma

References

• Kyle RA, Rajkumar SV. Multiple myeloma. N. Engl. J. Med.351(18), 1860–1873 (2004).
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J. Clin. Oncol.23(15), 3412–3420 (2005).
   PubMed Web of Science ®Google Scholar
• Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J. Clin. Oncol.23(26), 6339–6344 (2005).
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene20(40), 5611–5622 (2001).
   PubMed Web of Science ®Google Scholar
• Chng WJ, Santana-Davila R, Van Wier SA et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia20(5), 807–813 (2006).
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood106(1), 296–303 (2005).
   PubMed Web of Science ®Google Scholar
• Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood105(1), 358–360 (2005).
   PubMed Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S et al. The molecular classification of multiple myeloma. Blood108(6), 2020–2028 (2006).
   PubMed Web of Science ®Google Scholar
• Hanamura I, Stewart JP, Huang Y et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood108(5), 1724–1732 (2006).
   PubMed Web of Science ®Google Scholar
• Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology10(Suppl. 1), 117–126 (2005).
   PubMed Web of Science ®Google Scholar
• Zhan F, Colla S, Wu X et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood109(11), 4995–5001 (2007).
   PubMed Web of Science ®Google Scholar
• Fonseca R, Oken MM, Harrington D et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia15(6), 981–986 (2001).
   PubMed Web of Science ®Google Scholar
• Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am. Soc. Hematol. Educ. Program346–352 (2005).
   PubMedGoogle Scholar
• Fonseca R, Hoyer JD, Aguayo P et al. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. Leuk. Lymphoma35(5–6), 599–605 (1999).
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood101(4), 1570–1571 (2003).
   PubMed Web of Science ®Google Scholar
• Fonseca R, Blood EA, Oken MM et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood99(10), 3735–3741 (2002).
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood106(8), 2837–2840 (2005).
   PubMed Web of Science ®Google Scholar
• Chang H, Qi XY, Stewart AK. t(11;14) does not predict long-term survival in myeloma. Leukemia19(6), 1078–1079 (2005).
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Brents LA et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet.16(3), 260–264 (1997).
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood92(9), 3025–3034 (1998).
   PubMed Web of Science ®Google Scholar
• Keats JJ, Maxwell CA, Taylor BJ et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood105(10), 4060–4069 (2005).
   PubMed Web of Science ®Google Scholar
• Trudel S, Stewart AK, Rom E et al. The inhibitory anti-FGFR3 antibody, PRO-001 is cytotoxic to t(4;14) multiple myeloma cells. Blood107(10), 4039–4046 (2006).
   PubMed Web of Science ®Google Scholar
• Trudel S, Li ZH, Wei E et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood105(7), 2941–2948 (2005).
   PubMed Web of Science ®Google Scholar
• Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood106(1), 353–355 (2005).
   PubMed Web of Science ®Google Scholar
• Chang H, Sloan S, Li D et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br. J. Haematol.125(1), 64–68 (2004).
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Moreau P et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood109(8), 3489–3495 (2007).
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol. Rev.194, 96–104 (2003).
   PubMed Web of Science ®Google Scholar
• Chesi M, Bergsagel PL, Shonukan OO et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood91(12), 4457–4463 (1998).
   PubMed Web of Science ®Google Scholar
• Fonseca R, Harrington D, Oken MM et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (δ13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res.62(3), 715–720 (2002).
   PubMed Web of Science ®Google Scholar
• Fonseca R, Blood E, Rue M et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood101(11), 4569–4575 (2003).
   PubMed Web of Science ®Google Scholar
• Fonseca R, Debes-Marun CS, Picken EB et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood102(7), 2562–2567 (2003).
   PubMed Web of Science ®Google Scholar
• Shaughnessy J Jr, Zhan F, Barlogie B, Stewart AK. Gene expression profiling and multiple myeloma. Best Pract. Res. Clin. Haematol.18(4), 537–552 (2005).
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr, Barlogie B. Using genomics to identify high-risk myeloma after autologous stem cell transplantation. Biol. Blood Marrow Transplant.12(1 Suppl. 1), 77–80 (2006).
   PubMedGoogle Scholar
• Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br. J. Haematol.127(3), 280–284 (2004).
   PubMed Web of Science ®Google Scholar
• Chang H, Qi XY, Samiee S et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant.36(9), 793–796 (2005).
   PubMed Web of Science ®Google Scholar
• Chang H, Bouman D, Boerkoel CF, Stewart AK, Squire JA. Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia13(1), 105–109 (1999).
   PubMed Web of Science ®Google Scholar
• Facon T, Avet-Loiseau H, Guillerm G et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood97(6), 1566–1571 (2001).
   PubMed Web of Science ®Google Scholar
• Fassas AB, Spencer T, Sawyer J et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br. J. Haematol.118(4), 1041–1047 (2002).
   PubMed Web of Science ®Google Scholar
• Fonseca R, Barlogie B, Bataille R et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res.64(4), 1546–1558 (2004).
   PubMedGoogle Scholar
• Sawyer JR, Tricot G, Lukacs JL et al. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer42(1), 95–106 (2005).
   PubMed Web of Science ®Google Scholar
• Fonseca R, Van Wier SA, Chng WJ et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia20(11), 2034–2040 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br. J. Haematol.122(3), 441–450 (2003).
   PubMed Web of Science ®Google Scholar
• Barlogie B, Smallwood L, Smith T, Alexanian R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann. Intern. Med.110(7), 521–525 (1989).
   PubMed Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Fritsche H. β2 microglobulin in multiple myeloma. Am. J. Hematol.20(4), 345–351 (1985).
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc.78(1), 21–33 (2003).
   PubMed Web of Science ®Google Scholar
• Pardanani A, Witzig TE, Schroeder G et al. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood101(3), 827–830 (2003).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Fonseca R, Lacy MQ et al. β2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant.23(12), 1261–1266 (1999).
   PubMed Web of Science ®Google Scholar
• Greipp PR, Lust JA, O’Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood81(12), 3382–3387 (1993).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann. Intern. Med.115(12), 931–935 (1991).
   PubMed Web of Science ®Google Scholar
• Tricot G, Spencer T, Sawyer J et al. Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br. J. Haematol.116(1), 211–217 (2002).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Fonseca R, Dewald GW et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet. Cytogenet.113(1), 73–77 (1999).
   PubMed Web of Science ®Google Scholar
• Steensma DP, Gertz MA, Greipp PR et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood97(8), 2522–2523 (2001).
   PubMed Web of Science ®Google Scholar
• Chng WJ, Ahmann GJ, Henderson K et al. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood107(9), 3669–3675 (2006).
   PubMed Web of Science ®Google Scholar
• Wilson CS, Butch AW, Lai R et al. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy. Br. J. Haematol.112(3), 776–782 (2001).
   PubMed Web of Science ®Google Scholar
• Robillard N, Avet-Loiseau H, Garand R et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood102(3), 1070–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Hurt EM, Wiestner A, Rosenwald A et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell5(2), 191–199 (2004).
   PubMed Web of Science ®Google Scholar
• Greipp PR, Trendle MC, Leong T et al. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk. Lymphoma35(1–2), 83–89 (1999).
   PubMed Web of Science ®Google Scholar
• Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood98(7), 2229–2238 (2001).
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Orfao A, Gonzalez M et al. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br. J. Haematol.90(1), 106–112 (1995).
   PubMed Web of Science ®Google Scholar
• Stewart AK, Bergsagel PL, Greipp PR et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia21(3), 529–534 (2007).
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Rajkumar SV, Gertz MA et al. Treatment of newly diagnosed multiple myeloma based on mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement. Mayo Clin. Proc.82(3), 323–341 (2007).
   PubMed Web of Science ®Google Scholar